| Primary information |
|---|
| sequence ID | Seq_5622 |
| Peptide sequence | NGERIEKVEHSDL |
| CancerPDF_ID | CancerPDF_ID3591, |
| PMID | 27026199 |
| Protein Name | "Beta-2-microglobulin form pI 5,3; B2M" |
| UniprotKB Entry Name | B2M_HUMAN |
| Fluid | Urine |
| fdr | 1524.65 |
| Profiling Technique | "CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS |
| Labelled/Label Free | Label Free |
| CancerPDF_ID | CancerPDF_ID3591, |
| p-Value | less than 0.05 |
| Software | Proteome Discoverer 1.2 |
| Length | 13 |
| Cancer Type | Bladder cancer |
| Database | Uniprot Human non-redundant Database |
| Modification | NA |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation |
| Sensitivity | For testing dataset 88% |
| Specificity | For testing dataset 51% |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |